March 23, 2026
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 17, 2026
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 12, 2026
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 2, 2026
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 2, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 11, 2026
Xilio Therapeutics Announces Pricing of Underwritten Offering
January 8, 2026
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates